Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FDL169 in Healthy Female Volunteers
NCT02680418Phase 1Completed
- Sponsor
- Flatley Discovery Lab
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FDL169 in cystic fibrosis (CF) (6 arms), sponsored by Flatley Discovery Lab. Primary endpoints: Maximum plasma concentration at 48 hours, Time to maximum plasma concentration at 48 hours and 3 more. Started Dec 2015; status: completed.
02
Drugs
FDL169
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02680418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680418.